Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, January 9, 2020
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
[ Thu, Jan 09th 2020
] - WOPRAI
Madhu Kumar Maintained (ABUS) at Strong Buy with Increased Target to $6 on, Jan 9th, 2020
Madhu Kumar of B. Riley Securities, Maintained "Arbutus Biopharma Corporation" (ABUS) at Strong Buy with Increased Target from $3 to $6 on, Jan 9th, 2020.
Madhu has made no other calls on ABUS in the last 4 months.
There is 1 other peer that has a rating on ABUS. Out of the 1 peers that are also analyzing ABUS, all agrees with Madhu's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Keay Nakae of "Chardan Capital" Downgraded from Strong Buy to Hold on, Friday, October 4th, 2019
